Femto-LASIK outperformed

Article

Moria's new microkeratome, One Use-Plus SBK, outperforms Femto-LASIK, it was announced at this year's meeting of the American Society of Cataract and Refractive Surgery (ASCRS).

Moria's new microkeratome, One Use-Plus SBK, outperforms Femto-LASIK, it was announced at this year's meeting of the American Society of Cataract and Refractive Surgery (ASCRS).

Richard J. Duffey, MD of Premier Medical Eye Group, Alabama, US compared flap thickness predictability, speed of visual recovery, higher order aberrations, smoothness of stromal bed and patient comfort between the two techniques. Dr Duffey has no financial interest in Moria or the One Use-Plus SBK.

For every variable, the One Use-Plus compared equally or favourably with Femto-LASIK, with none of the associated complications of the latter device. Postoperative pain in the first one to five hours was lower in both frequency and intensity when using the One Use-Plus than with Femto-LASIK.

Dr Duffey concluded that the One Use-Plus was a better option for both patients and surgeons than Femto-LASIK.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.